- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
- Interventions
- inhaled mosliciguat, Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Pulmovant, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 14,759
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Interventions
- stereotactic body radiation therapy, carboplatin, paclitaxel, radiation therapy
- Radiation · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • St Louis, Missouri
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- CAL101, Placebo
- Drug
- Lead sponsor
- Calluna Pharma AS
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Miami, Florida + 6 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cystic Fibrosis
- Interventions
- Doxycycline, placebo
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Portopulmonary Hypertension
- Interventions
- Ambrisentan
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 6
- States / cities
- La Jolla, California • Jacksonville, Florida • Boston, Massachusetts + 3 more
- Conditions
- Pulmonary Disease, COPD, Chronic Bronchitis, Emphysema
- Interventions
- Audit and Feedback
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Premature Lungs, Respiratory Distress Syndrome, Surfactant Deficiency Syndrome Neonatal
- Interventions
- Less Invasive Surfactant Administration LISA, Continuous Positive Airway Pressure CPAP
- Procedure
- Lead sponsor
- Sharp HealthCare
- Other
- Eligibility
- 24 Weeks to 29 Weeks
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Irvine, California • Loma Linda, California • San Diego, California
- Conditions
- Lung Cancer, Pulmonary Complications
- Interventions
- educational intervention, supervised exercise program
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 60
- States / cities
- Fort Collins, Colorado • Decatur, Illinois • Maywood, Illinois + 32 more
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Ifinatamab Deruxtecan (I-DXd)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 16
- States / cities
- Springdale, Arkansas • Jacksonville, Florida • Tampa, Florida + 13 more
- Conditions
- Gastrointestinal Carcinoid Tumor, Lung Cancer
- Interventions
- recombinant interferon alfa, fluorouracil
- Biological · Drug
- Lead sponsor
- Mid-Atlantic Oncology Program
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1990 – 2004
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Interventions
- Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 56 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Acalabrutinib
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Cystic Fibrosis
- Interventions
- SB656933
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Minneapolis, Minnesota • Pittsburgh, Pennsylvania
- Conditions
- Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Osteogenic Sarcoma Recurrent
- Interventions
- Iscador*P
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 8 Years to 30 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Hackensack, New Jersey • Houston, Texas
- Conditions
- Asthma
- Interventions
- ONO-6950, Montelukast, Placebo
- Drug
- Lead sponsor
- Ono Pharma USA Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Diego, California • Denver, Colorado + 6 more
- Conditions
- Breast Cancer, Gastrointestinal Cancer, Lung Cancer (Diagnosis), Prostate Cancer (Diagnosis), Head and Neck Cancer (H&N), Bladder Cancer
- Interventions
- MyPatientPal+
- Behavioral
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Long COVID, Chronic Fatigue Syndrome
- Interventions
- Transcutaneous vagus nerve stimulator
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML), Multiple Myeloma, Prostate Cancer, Small Cell Lung Cancer, Non-Hodgkins Lymphoma
- Interventions
- ABBV-075, Venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Duarte, California • Sacramento, California + 6 more
- Conditions
- Neoplasms, Heart Failure, Kidney Diseases, Lung Diseases
- Interventions
- Making Your Wishes Known, Standard advance care planning
- Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Hershey, Pennsylvania
- Conditions
- Asthma, Wheezing
- Interventions
- Azithromycin, Placebo
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Months to 60 Months
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • New York, New York + 5 more
- Conditions
- COVID-19
- Interventions
- Lactobacillus Plantarum 299v Freeze Dried Capsule, Freeze Dried Potato Starch Capsule
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Lung Cancer
- Interventions
- Bevacizumab, Pemetrexed, Radiotherapy, Folic Acid, vitamin B12, carboplatin
- Drug · Procedure · Other
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 7
- States / cities
- Gainesville, Florida • Lakeland, Florida • Marietta, Georgia + 4 more